Doximity (DOCS) Company Report

Doximity reported strong fiscal Q3 2026 results, with revenue of $185 million, a 10% year-over-year increase, and an Adjusted EBITDA margin of 60%.
For fiscal Q4 2026, the company expects revenue between $143 million and $144 million and Adjusted EBITDA between $63.5 million and $64.5 million. The full fiscal year 2026 revenue guidance is $642.5 million to $643.5 million, with an Adjusted EBITDA margin of 55%.
CFO Anna Bryson is on medical leave, with Audit Committee Chair Tim Cabral assisting with financials.
Doximity saw significant adoption of its AI products, with over 300,000 unique prescribers using them and over 100 top health systems purchasing its AI suite. The company also repurchased $196.8 million in shares and authorized a new $500 million open-ended repurchase program.
The annual selling season was impacted by policy headwinds, specifically Most Favored Nation (MFN) deals with top pharma companies, leading to delayed bookings and lower upfront budget deployment, which affected Q4 revenue expectations.

1 day ago

Transcript

Doximity Reports Strong Q3 2026 Results, Updates Guidance, and Announces CFO Medical Leave

DOCS

Earnings

Guidance Update

CFO Change

Doximity reported Q3 2026 revenue of $185 million, a 10% year-on-year growth, and an adjusted EBITDA margin of 60%, exceeding the high end of guidance for both metrics.
The company issued Q4 FY2026 revenue guidance of $143 million-$144 million and full FY2026 revenue guidance of $642.5 million-$643.5 million, noting that the annual outlook midpoint remained consistent due to lower Q4 expectations and increased AI infrastructure investments.
Over 300,000 unique prescribers used Doximity's AI products in Q3 2026, and 100 top health systems purchased its AI suite for over 180,000 prescribers.
Doximity repurchased $196.8 million worth of shares in Q3 2026 and announced a new $500 million open-ended share repurchase authorization.
CFO Anna Bryson is on medical leave, with Audit Committee Chair Tim Cabral stepping in to discuss financials.

1 day ago

Transcript

Doximity Reports Strong Q3 2026 Results, Announces New Share Repurchase, and Updates Guidance

DOCS

Earnings

Guidance Update

Share Buyback

Doximity reported strong Q3 2026 revenue of $185 million, marking 10% year-on-year growth, and an Adjusted EBITDA margin of 60%, or $111 million.
The company announced a new $500 million open-ended share repurchase authorization, supplementing the $83 million remaining from the existing program, after repurchasing $196.8 million in Q3.
For Q4 2026, Doximity expects revenue between $143 million and $144 million (4% growth at midpoint), and full fiscal year 2026 revenue guidance is set at $642.5 million to $643.5 million (13% growth at midpoint).
Despite Q3 outperformance, Q4 revenue expectations are lower due to policy headwinds, including Most Favored Nation agreements impacting pharma client budget deployment, though the company anticipates exiting calendar year 2026 as a double-digit grower.
AI product adoption is significant, with 300,000 unique prescribers using AI tools in Q3 and over 100 health systems purchasing the AI suite for 180,000 prescribers, with commercial AI products expected later in the year but no AI revenue currently in guidance.

1 day ago

Transcript

Doximity Announces Fiscal 2026 Third Quarter Financial Results and Share Repurchase Program

DOCS

Earnings

Guidance Update

Share Buyback

Doximity reported Q3 Fiscal 2026 revenue of $185.1 million, a 10% increase year-over-year, with net income of $61.6 million and adjusted EBITDA of $111.4 million for the quarter ended December 31, 2025.
The company provided Q4 Fiscal 2026 revenue guidance between $143 million and $144 million and adjusted EBITDA guidance between $63.5 million and $64.5 million.
For the full fiscal year ending March 31, 2026, Doximity updated its revenue guidance to be between $642.5 million and $643.5 million and adjusted EBITDA guidance to be between $355.5 million and $356.5 million.
Doximity's board of directors authorized a new program to repurchase up to $500 million of its Class A common stock.

1 day ago

8-K

Doximity Announces Fiscal 2026 Third Quarter Financial Results

DOCS

Earnings

Guidance Update

Share Buyback

Doximity reported fiscal 2026 third quarter revenue of $185.1 million, marking a 10% increase year-over-year, with net income of $61.6 million and Adjusted EBITDA of $111.4 million.
Diluted net income per share for the quarter was $0.31, while non-GAAP diluted net income per share was $0.46.
The company provided fiscal fourth quarter 2026 revenue guidance between $143 million and $144 million and updated its full fiscal year 2026 revenue guidance to between $642.5 million and $643.5 million.
Doximity's board of directors authorized a new stock repurchase program of up to $500 million of its Class A common stock.

1 day ago

Press Release

Doximity Reports Strong Q2 Fiscal 2026 Results with Revenue Growth and AI Expansion

DOCS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Doximity reported strong financial results for the second quarter of fiscal 2026, with revenues rising 23.2% year over year to $168.5 million and adjusted earnings per share increasing 50% year over year to 45 cents.
The company experienced significant operational growth, including over 50% growth in AI Scribe and DoxGPT users and an expanded user base of 650,000 prescribers, contributing to $159.5 million in subscription revenues.
Doximity maintains a strong financial position with $169.2 million in cash and cash equivalents and projects fiscal year 2026 revenue between $640 million and $646 million and adjusted EBITDA between $351 million and $357 million.

Nov 7, 2025, 12:14 PM

Morningstar

DOCS Reports Strong Q2 2026 Results and Raises Full-Year Guidance

DOCS

Earnings

Guidance Update

Product Launch

DOCS reported strong Q2 2026 financial results with revenue of $168.5 million, a 23% year-over-year increase, and an adjusted EBITDA of $100.8 million, achieving a 60% margin.
The company raised its full fiscal year 2026 guidance, now expecting revenue between $640 million and $646 million and adjusted EBITDA between $351 million and $357 million, primarily due to the outperformance of its pharma business.
AI product adoption saw significant growth, with quarterly active prescribers of AI tools increasing over 50% from the prior quarter, and Doximity Scribe users nearly tripling versus Q1. The recent Pathway acquisition was fully integrated, enhancing Docs GPT with drug reference and access to over 2,000 medical journals.
AI-optimized integrated programs now account for over 40% of Q2 bookings, a substantial increase from less than 5% a year ago, leading to a more consistent and strategic upsell cycle.

Nov 6, 2025, 10:00 PM

Transcript

DOCS Reports Strong Q2 2026 Financials and AI Product Growth

DOCS

Earnings

Guidance Update

Product Launch

For the second quarter of fiscal year 2026, DOCS reported $168.5 million in revenue, representing 23% year-on-year growth, and an adjusted EBITDA of $100.8 million, with a 60% margin. Free cash flow increased 37% year-on-year to $91.6 million.
The company's AI initiatives saw significant progress, with the Pathway acquisition fully integrated into Docs GPT within seven weeks, enhancing its drug reference and medical journal access capabilities. Quarterly active users for AI Scribe nearly tripled versus Q1.
DOCS provided guidance for Q3 2026, expecting revenue between $180 million and $181 million and adjusted EBITDA between $103 million and $104 million. For the full fiscal year 2026, revenue is projected to be between $640 million and $646 million, with adjusted EBITDA between $351 million and $357 million.
Integrated programs, which are AI-optimized, represented over 40% of bookings in Q2, a significant increase from less than 5% a year ago, contributing to a stronger than typical Q2 and a more evenly distributed upsell cycle.
DOCS continued to gain market share, growing at about two times the market growth rate for calendar year 2025, with a 15% growth rate compared to an estimated market growth of 5% to 7%.

Nov 6, 2025, 10:00 PM

Transcript

Doximity Reports Strong Q2 2026 Financials and Raises Full-Year Guidance

DOCS

Earnings

Guidance Update

Product Launch

Doximity (DOCS) reported Q2 FY2026 revenue of $169 million, a 23% year-on-year increase, and an Adjusted EBITDA of $101 million, achieving a 60% margin.
The company raised its full fiscal year 2026 revenue guidance to a range of $640 million to $646 million and Adjusted EBITDA guidance to $351 million to $357 million.
Key growth drivers include AI-optimized integrated programs, which comprised over 40% of Q2 bookings (up from less than 5% a year ago), and a 100% year-over-year growth in SMB bookings.
Operational success was marked by a 50% increase in quarterly active prescribers utilizing AI tools and a nearly tripled number of quarterly active users for AI Scribe compared to Q1.
Doximity maintained a strong financial position with $878 million in cash, cash equivalents, and marketable securities and repurchased $21.9 million in shares during the quarter.

Nov 6, 2025, 10:00 PM

Transcript

Doximity Announces Fiscal Q2 2026 Financial Results and Updates Guidance

DOCS

Earnings

Guidance Update

Doximity reported total revenues of $168.5 million for its fiscal second quarter ended September 30, 2025, representing a 23% increase year-over-year.
Operating cash flow for Q2 2026 was $93.9 million, and free cash flow was $91.6 million, both up 37% year-over-year.
Adjusted EBITDA for the quarter increased 32% year-over-year to $100.8 million, achieving a 59.8% margin.
For fiscal Q3 2026, Doximity expects revenue between $180 million and $181 million and adjusted EBITDA between $103 million and $104 million.
The company updated its fiscal year 2026 guidance, projecting revenue between $640 million and $646 million and adjusted EBITDA between $351 million and $357 million.

Nov 6, 2025, 9:08 PM

8-K

Fintool News

In-depth analysis and coverage of Doximity.

Corporate

Doximity CFO Takes Medical Leave as Stock Hits 52-Week Low on Q3 Earnings

Yesterday

View all news

Earnings Transcripts

Quarterly earnings call transcripts for Doximity.

Q3 2026

Feb 5, 2026

→

Q2 2026

Nov 6, 2025

→

Q1 2026

Aug 7, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Jeff Tangney say about margins?What are Doximity's strategic priorities?How is Doximity positioned vs competitors?How did Doximity do last quarter?

Doximity (DOCS)

Analyst Earnings Quarterly Reports

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q3 2026

Executives

Jeff Tangney

Anna Bryson

John Vaughan

Board Members

Kevin Spain

Kira Wampler

Phoebe Yang

Regina Benjamin

Timothy Cabral

Analyst Coverage

Allen Lutz

Elizabeth Anderson

Scott Schoenhaus

Brian Peterson

Craig Hettenbach

Ryan MacDonald

David Roman

Michael Cherny

Stan Berenshteyn

Richard Close

Ryan Daniels

Steven Valiquette

Brian Tanquilut

Eric Percher

Jailendra Singh

David Larsen

Glenn Santangelo

Glen Santangelo

Jared Haase

Jeff Garro

Jeffrey Garro

Jenny Cao

Jessica Tassan

Michael Turney

Ryan Halsted

Alexei Gogolev

Anne McCormick

Anne Samuel

Daniel Christopher Clark

Derek Gross

Jamie Perse

Jenny Shen

Johnathan McCary

John Park

Nate Gross

Scott Berg

Stanislav Berenshteyn

Stephanie Davis

Vikram Kesavabhotla

Latest news

Fintool News

Doximity CFO Takes Medical Leave as Stock Hits 52-Week Low on Q3 Earnings

Earnings Transcripts

Q3 2026

Q2 2026

Q1 2026

Ask Fintool AI Agent